Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Comparisons of Subjective and Objective Motor and Non-motor Symptoms in Isolated REM Sleep Behavior Disorder in the North American Prodromal Synucleinopathy (NAPS) Cohort

Author:Reddy, Neha   Nie, Yuzheng   De La Cruz, Hernis   Xiong, Chengjie   Avidan, Alon   Bliwise, Don   Campbell, Meghan   Criswell, Susan   Davis, Albert   Duff, Kevin   Elliott, Jonathan   Ferman, Tanis   Forsberg, Leah   Gagnon, Jean-Francois   Howell, Michael   Huddleston, Daniel   Lim, Miranda   Locke, Jessica   McLeland, Jennifer   Miglis, Mitchell   Miyagawa, Toji   Neilson, Lee   Nichols, Kendall   Pelletier, Amelie   Schenck, Carlos   St. Louis, Erik   Sum-Ping, Oliver   Trotti, LynnMarie   Videnovic, Aleksandar   Postuma, Ronald   Ju, Yo-El   Fields, Julie   Boeve, Bradley   McCarter, Stuart   

Session Name:S3: Research Advances in Sleep and Clinical Impact  

Topic:Sleep  

Program Number:S3.005  

Author Institution:Mayo Clinic, Rochester, MN  Washington University School of Medicine, MO  Washington University School of Medicine, St. Louis, MO  David Geffen School of Medicine at UCLA, Los Angeles, CA  Emory School of Medicine, GA  Washington University in St. Louis, Saint Louis, MO  Washington University, Saint Louis, MO  Oregon Health & Science University, OR  Oregon Health & Science University, Portland, OR  Mayo Clinic Jacksonville, Jacksonville, FL  Centre D'etude Du Sommeil, Montreal, QC, Canada  University of Minnesota, Minneapolis, MN  Emory University, Atlanta, GA  VA Portland Health Care System, Portland, OR  OHSU Neurology, Portland, OR  Stanford University Medical Center, Stanford, CA  Oregon Health & Science University, Iowa City, IA  Emory University, GA  Montreal General Hospital, Montreal, QC, Canada  Minnesota Regional Sleep Disorders Center, Minneapolis, MN  Stanford University, Redwood City, CA  Emory University School of Medicine, Atlanta, GA  MGH Neurological Clinical Research Institute, Boston, MA  Washington University School of Medicine, Saint Louis, MO  

ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease

Author:Giovannoni, Gavin   Airas, Laura   Bove, Riley   Cutter, Gary   Hobart, Jeremy   Kuhle, Jens   Montalban, Xavier   Tur, Carmen   Wolinsky, Jerry   Schneble, Hans-Martin   Baldinotti, Anna   Bonati, Ulrike   Giacobino, Caroline   Wang, Qing   Yang, Ke   Oh, Jiwon   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.001  

Author Institution:Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK and Blizard Institute, Queen Mary University, London, UK, London, United Kingdom  University of Turku, Turku, Finland, Turku, Finland  UCSF Weill Institute for Neuroscience, Department of Neurology, University of California San Francisco, San Francisco, CA, USA, CA  The University of Alabama at Birmingham, School of Public Health, Birmingham, AL, USA, Birmingham, AL  Peninsula Medical School, Plymouth University, UK, Plymouth, United Kingdom  MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland, Switzerland  Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Queen Square MS Centre, Department of Neuroinflammation, Institute of Neurology, Faculty of Brain Sciences, University College London (UCL), London, UK/Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (CEMCAT), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, Un  Department of Neurology, University of Texas Health Science Center, Houston, TX, USA, TX  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Switzerland  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada, ON, Canada  

Clinical, Instrumental, and Prognostic Definitions of de novo Central Nervous System Demyelinating Disorders Following Immune Checkpoint Inhibitor Therapy

Author:Masciocchi, Stefano   Malvaso, Antonio   Bihan, Kevin   Dinoto, Alessandro   Farina, Antonio   Picca, Alberto   Izquierdo Gracia, Cristina   Martín-Aguilar, Lorena   Bruna-Escuer, Jordi   Damato, Valentina   Sechi, Elia   Rossi, Simone   De Rossi, Nicola   Ariño, Helena   Cobo-Calvo, Alvaro   Mariotto, Sara   Joubert, Bastien   Marchioni, Enrico   Vogrig, Alberto   Gastaldi, Matteo   

Session Name:P6: Autoimmune Neurology: Immune Checkpoint Inhibitor and CAR-T 1  

Topic:Autoimmune Neurology  

Program Number:P6.001  

Author Institution:Neuroimmunology Laboratory and Neuroimmunology Research Section, IRCCS Mondino Foundation, Pavia, Italy, Italy  Department of Pharmacology, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Paris (AP-HP), Clinical Investigation Center (CIC-1901), Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France, France  Neuroimmunology and Neuromuscular Disease Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Italy  French Reference Centre on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, 59 Boulevard Pinel, 69677, Bron Cedex, France, France  Neuro-Oncology Service, AP-HP, Pitié-Salpêtrière Hospital and Sorbonne Université, Paris, France, France  Multiple Sclerosis Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain, Spain  Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Spain  Neuro-Oncology Unit, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain, Italy  Department of Neuroscience, University of Florence, Florence, Italy  University of Sassari, Sassari, Italy  IRCCS Istituto delle Scienze Neurologiche di Bologna (S.R., R.R., M. Guarino), Italy, Italy  ASST-Spedali Civili di Brescia, Montichiari, Italy, Italy  Neurology Department, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain, Spain  Neurology Unit, University of Verona, Verona, Italy  Hospices Civils de Lyon, Saint-Genis-Laval, France  Neuroncology and Neuroinflammation Unit, IRCCS Mondino Foundation, Pavia, Italy, Pavia, Italy  Department of Medicine (DMED), University of Udine, Udine, Italy  Clinical Neurology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Italy  IRCCS Mondino Foundation, Pavia, Italy  

Ofatumumab Treatment Up to Eight Years Shows a Favorable and Consistent Safety Profile in People Living With Relapsing Multiple Sclerosis